VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd, has received human ethics approval from the Human Research Ethics Committee of The Peter MacCallum Cancer Centre for its Phase II clinical study in Pancreatic Cancer.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce the signing of a licence agreement to expand PromarkerD's reach in Central and South America.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the Chairman's Address provided by Mr Neville Gardiner and the Investor Presentation provided by Dr Richard Lipscombe to shareholders.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce that the US Centers for Medicare & Medicaid Services has published its final determination of the national reimbursement price in the United States for the PromarkerD predictive test for diabetic kidney disease.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to provide an opportunity for shareholders and investors to view a virtual presentation by Managing Director Dr Richard Lipscombe.
Proteomics International Laboratories Ltd (ASX:PIQ) announces that its cash reserves have been further strengthened by the receipt of $1.85 million in research and development tax incentive for the 2022-23 financial year.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of its latest investor presentation for a non-deal roadshow to institutional investors.
